Los Angeles, CA (PRWEB) May 02, 2013 The diabetes drug safety advocates at DrugRisk.com are announcing new information on the site for those taking the medication Januvia. A recent study suggests the drug may have higher occurrence rates of pancreatitis and pancreatic cancer than traditional pills****. DrugRisk was created to improve patient safety by providing the latest warnings, recalls, studies and legal news to those taking popular prescription drugs. Visitors can see if others are experiencing similar side effects and decide if they need legal advice. Januvia is a once-a-day pill introduced in 2006 to help those with type-2 diabetes control blood sugar. It has become Mercks best-selling drug, with sales of over $4 billion last year*. However, a 2011 study from UCLA indicated the drug could increase the risk of pancreatic cancer by 272% and thyroid cancer by 148%**. The Journal for the American Medical Association also recently warned Januvia could double the risk of pancreatitis, a major risk factor for pancreatic cancer***. Now, DrugRisk has added a new study by the Institute for Safe Medication Practices, which found in an analysis of FDA reports that patients were 20.8 times as likely to report pancreatitis or pre-cancerous growth from … Continue reading →

New York, NY (PRWEB) May 02, 2013 The diabetes drug safety advocates at DrugRisk.com are announcing new information on the site for patients who have taken the diabetes medication Actos. A jury in the first Actos trial last week decided that the maker of the drug didnt properly warn patients of bladder cancer risks****. The goal of DrugRisk is to improve the safety of patients taking popular prescription drugs by providing the most up-to-date warnings, recalls, studies and legal news. Visitors can determine if others have experienced similar side effects and decide if they need legal advice. DrugRisk contains warnings from experts such as the FDA and European Medicines Agency*, who have warned that long-term use of Actos may be associated with an increased bladder cancer risk. The drug has also been banned in France and Germany**. Although Actos remains on the market in the United States, the resource center notes that as many as 3,000 patients have filed an Actos lawsuit against drug maker Takeda Pharmaceuticals alleging they developed bladder cancer***. Now, DrugRisk has learned that, in the first of those lawsuits to go to trial, a jury last week decided that drug maker Takeda failed to properly warn … Continue reading →

St. Louis, MO (PRWEB) May 03, 2013 The birth control safety advocates at DrugRisk.com are announcing updated news for women who have used the contraceptive NuvaRing. Financial records released by Merck this week show sales of the device have slowed from the end of last year*. The goal of DrugRisk is to improve the safety of patients using popular prescription drugs and devices by providing them with the latest drug news, warnings, research and legal news. Visitors can find out if others are experiencing similar side effects and decide if they need legal advice. Health experts have linked contraceptives like NuvaRing to higher risks of blood clots than traditional birth control pills. Last year, the New England Journal of Medicine published a study finding vaginal ring contraceptives could relate to a 2.5 to 3-fold increased risk of blood clots**. So far, nearly 1,100 patients have filed a NuvaRing lawsuit alleging blood clots in a special federal court in Missouri. The formal case is known as In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri. U.S. District Judge Rodney Sippel recently scheduled the first trial to start in October***. Now, DrugRisk has obtained the latest financial records from … Continue reading →